FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 凱萊英醫藥集團（天津）股份有限公司 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06821 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 27,834,510 | RMB | | 1 RMB | | 27,834,510 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 27,834,510 | RMB | | 1 RMB | | 27,834,510 | | 2. 股份分類 | 普通股 | 股份類別 ...

Group 1 - Kailaiying's stock price has dropped 2.05% to 92.50 CNY per share, with a total market capitalization of 33.381 billion CNY, and a cumulative decline of 7.07% over the last four days [1] - The company, established on October 7, 1998, and listed on November 18, 2016, primarily provides CMO pharmaceutical outsourcing services, with revenue composition of 76.19% from small molecule CDMO solutions, 23.71% from emerging services, and 0.10% from other sources [1] Group 2 - Morgan Fund holds 3,500 shares of Kailaiying in its Morgan Antong Return Mixed A fund, representing 1.24% of the fund's net value, ranking as the fifth largest holding [2] - The fund has experienced a floating loss of approximately 6,790 CNY today and a total floating loss of 24,600 CNY during the four-day decline [2] - Morgan Antong Return Mixed A fund, established on April 26, 2017, has a total scale of 13.6117 million CNY, with a year-to-date return of 2.8% and a one-year return of 13.85% [2]

香港联交所最新资料显示，2月10日，小摩增持凯莱英（002821）(06821)9400股，每股作价87.5591港 元，总金额约为82.31万港元。增持后最新持股数目约为167.41万股，最新持股比例为6.01%。 ...

智通财经APP获悉，香港联交所最新资料显示，2月10日，小摩增持凯莱英(06821)9400股，每股作价 87.5591港元，总金额约为82.31万港元。增持后最新持股数目约为167.41万股，最新持股比例为6.01%。 ...

Group 1 - The core point of the article is that JPMorgan has increased its stake in Kairong Pharmaceutical (06821) by purchasing 4,700 shares at a price of 80.6776 HKD per share, totaling approximately 379,200 HKD [1] - After the purchase, JPMorgan's total holdings in Kairong Pharmaceutical amount to approximately 1.6727 million shares, representing a holding percentage of 6% [1]

Core Viewpoint - JPMorgan has increased its stake in Kelaiying (002821) to approximately 6% by acquiring 4,700 shares at a price of HKD 80.6776 per share, totaling around HKD 379,200 [1] Group 1 - On February 4, JPMorgan purchased 4,700 shares of Kelaiying [1] - The total amount spent on the acquisition was approximately HKD 379,200 [1] - After the purchase, JPMorgan's total shareholding in Kelaiying reached approximately 1.6727 million shares [1]

Group 1 - Norges Bank increased its stake in Kairong (06821) by 53,500 shares at a price of HKD 79.0068 per share, totaling approximately HKD 4.2269 million [1] - After the increase, Norges Bank's total shareholding in Kairong reached 4.5065 million shares, representing a holding percentage of 16.19% [1]

Group 1 - Morgan Stanley reduced its stake in Kelaiying (002821) (06821) by 19,800 shares at a price of 78.6378 HKD per share, totaling approximately 1.557 million HKD [1] - After the reduction, Morgan Stanley's latest holding is approximately 1.668 million shares, representing a holding percentage of 5.99% [1]

Group 1 - Norges Bank increased its stake in Kelaiying (002821) (06821) by 53,500 shares at a price of HKD 79.0068 per share, totaling approximately HKD 4.2269 million [1] - After the increase, Norges Bank's total shareholding in Kelaiying reached 4.5065 million shares, representing a new ownership percentage of 16.19% [1]

Group 1 - Morgan Stanley reduced its stake in Kelaiying (06821) by 19,800 shares at a price of HKD 78.6378 per share, totaling approximately HKD 1.557 million [1] - After the reduction, Morgan Stanley's latest holding is approximately 1.668 million shares, representing a holding percentage of 5.99% [1]